FDA approved for a narrow indicationGrowth hormone-releasing factor analogIndication check required
Tesamorelin
Also known as GHRF analog
An approved GHRF analog whose labeled indication is substantially narrower than common wellness marketing suggests.
Education and decision support. This release does not generate doses, injection instructions, cycles, diagnoses, prescriptions, or vendor pathways.
What it is
Stimulates growth hormone release through the GHRH receptor, which can raise IGF-1.
FDA approved for a narrow indicationGH axis
Tesamorelin
An approved GHRF analog whose labeled indication is substantially narrower than common wellness marketing suggests.
ReceptorknownRoutessubcutaneousConfidencehigh
Visible for broad education until a goal is selected.
FDA approved for a narrow indication.
Useful for- Understanding indication-specific approval
- Evaluating whether clinic marketing matches the FDA label
Not established for- General weight-loss management
- Unmonitored longevity or body-composition protocols
Evidence receipts
FDA approved claimReviewed 2026-07-12
Excess abdominal fat in adults with HIV and lipodystrophyTesamorelin is FDA-approved for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.
The FDA label states it is not indicated for general weight-loss management.
